Login / Signup

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.

Carlos Escobar CervantesJulio Martí-AlmorAlejandro Isidoro Pérez CabezaKevin BowrinAleix Llorac MoixMar Genís GironèsDavid GascheAurélie MillierJean TarduMondher ToumiJean-Baptiste Brière
Published in: PloS one (2022)
These results suggest that rivaroxaban and dabigatran are cost-effective versus vitamin K antagonist for stroke prevention in non-valvular atrial fibrillation, from the Spanish National Health System perspective.
Keyphrases
  • atrial fibrillation
  • oral anticoagulants
  • catheter ablation
  • left atrial
  • left atrial appendage
  • direct oral anticoagulants
  • heart failure
  • percutaneous coronary intervention
  • venous thromboembolism